The key position of IL-6 at the crossroads of inflammation, innate and adaptive immunity, and the hallmarks of cancer (Fig. 1), provides major opportunities for novel therapy [Hunter and Jones, 2015; Jones and Jenkins, 2018; Propper and Balkwill, 2022; Dadgar et al., 2024]. Here, IL6 is linked to cancer.